GHR Peptide-6 vs TB-500
Research Verdict
TB-500 is the stronger research reference for the stated comparison criteria. TB-500 has the clearer direct preclinical repair study; neither compound has decision-grade human efficacy evidence.
Quick Answers
Which is better, GHR Peptide-6 or TB-500?
TB-500 is the stronger research reference for the stated comparison criteria. TB-500 has the clearer direct preclinical repair study; neither compound has decision-grade human efficacy evidence.
What is the key difference between GHR Peptide-6 and TB-500?
TB-500 is a thymosin beta-4-derived repair fragment; GHR-peptide-6 is a growth hormone secretagogue. Their mechanisms and research goals do not overlap.
Evidence Comparison
TB-500 fragment 17-23 has a positive 2026 rat tendon study but no established human exposure dataset. GHR-peptide-6 evidence comes mainly from one Cuban research group and includes human GH-response observations. Neither has a strong independent clinical efficacy record.
Evidence Context Favoring GHR Peptide-6
Growth hormone axis research, accepting single-group evidence and WADA prohibited status.
Evidence Context Favoring TB-500
Preclinical tendon-healing research where the direct 2026 animal study is relevant.
Side-by-Side Snapshot
| Evidence grade | GHR Peptide-6: Level D TB-500: Level C |
|---|---|
| Research status | GHR Peptide-6: Preclinical TB-500: Preclinical |
| Primary category | GHR Peptide-6: Healing & Recovery TB-500: Healing & Recovery |
| Cited studies | GHR Peptide-6: 2 TB-500: 9 |